X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.956375 0.053275 (5.9%) Market Cap: 160.61 Mil Enterprise Value: 129.34 Mil PE Ratio: 0 PB Ratio: 95.64 GF Score: 37/100

X4 Pharmaceuticals Inc Dr. Ragan Discusses X4's Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases Transcript

Dec 23, 2020 / NTS GMT
Release Date Price: $7.02 (+6.53%)
Unidentified Participant

Welcome to TrialSite News Podcast Series. Today, we are speaking with Dr. Paula Ragan, CEO of X4. Now X4 is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM syndrome in two Phase 1b trials for Waldenström macroglobulinemia, a type of rare lymphoma and a severe congenital neutropenia.

So doctor, welcome.

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

Thank you so much. Appreciate the chance to speak to you and your audience.

Questions & Answers

Unidentified Participant

Pleasure is ours. Now you made the leap to found X4 Pharmaceuticals a few years ago. What were the drivers to found this company?

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

For me it's all about the patients. I really am excited to figure out how to provide my gifts to people who have remaining unmet needs and kind of are under champion in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot